摘要
乙型肝炎病毒(Hepatitis B Virus, HBV)感染是世界上最常见的慢性病毒感染。在全球范围内,中国是HBV感染高发国家之一。乙肝病毒感染最大的健康问题是与慢性乙型病毒性肝炎(Chronic Hepatitis B, CHB)相关的风险,包括肝硬变、肝功能衰竭和肝细胞癌。目前的指南推荐核苷(酸)类似物(Nucleos(t)ide Analogues, NAs)作为CHB患者的首选抗病毒治疗方法。有效的抗病毒治疗,可通过降低风险和减缓甚至逆转肝病的进展,改变疾病的自然病程。近年来,对CHB患者治疗、预后等方面取得了研究成果,但对于CHB患者服药依从性的研究相对缺乏。本文对CHB患者服药依从性的现状进行综述,分析与抗病毒治疗依从性相关的影响因素,强调药物依从性的重要性,指出今后研究中应该更加关注如何提高依从性从而改善预后。
Hepatitis B Virus (HBV) infection is the most common chronic viral infection in the world. Globally, China is one of the countries with high prevalence of HBV infection. The biggest health concern of HBV infection is the risk associated with chronic hepatitis B (CHB), including liver cirrhosis, liver failure and hepatocellular carcinoma. Current guidelines recommend Nucleos(t)ide Analogues (NAs) as the preferred antiviral therapy for patients with CHB. Effective antiviral therapy can alter the natural course of the disease by reducing the risk and slowing or even reversing the progression of liver disease. In recent years, research results have been achieved on the treatment and prognosis of CHB patients, but there is a relative lack of research on medication adherence in CHB patients. In this paper, we review the current status of medication adherence in CHB patients, analyze the influencing factors related to adherence to antiviral therapy, emphasize the importance of medication adherence, and point out that more attention should be paid to how to improve adherence and thus improve the prognosis in future studies.
出处
《临床医学进展》
2024年第5期787-794,共8页
Advances in Clinical Medicine
